ES2165358T3 - Utilizaciones de la proteinquinasa de neurofilamento/tau pk40. - Google Patents

Utilizaciones de la proteinquinasa de neurofilamento/tau pk40.

Info

Publication number
ES2165358T3
ES2165358T3 ES92915162T ES92915162T ES2165358T3 ES 2165358 T3 ES2165358 T3 ES 2165358T3 ES 92915162 T ES92915162 T ES 92915162T ES 92915162 T ES92915162 T ES 92915162T ES 2165358 T3 ES2165358 T3 ES 2165358T3
Authority
ES
Spain
Prior art keywords
kinases
tau
neurofilament
proteinquinase
relating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92915162T
Other languages
English (en)
Inventor
Vernon M Ingram
Hanno M Roder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Application granted granted Critical
Publication of ES2165358T3 publication Critical patent/ES2165358T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

NUEVAS QUINASAS DE PROTEINA TAU/NEUROFILAMENTO PK40 Y PK36, SON ESENCIALMENTE PURIFICADAS Y CARACTERIZADAS. TAMBIEN ESTAN PREVISTAS NUEVAS PRUEBAS DE INMUNIDAD RELACIONADAS CON LAS QUINASAS E INHIBIDORES PARA LAS QUINASAS. FINALMENTE, SE PRESENTAN SECUENCIAS DNA QUE CODIFICAN LAS QUINASAS Y LAS LINEAS DE CELULAS RELACIONADAS CON LAS QUINASAS.
ES92915162T 1991-08-09 1992-07-10 Utilizaciones de la proteinquinasa de neurofilamento/tau pk40. Expired - Lifetime ES2165358T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74288091A 1991-08-09 1991-08-09

Publications (1)

Publication Number Publication Date
ES2165358T3 true ES2165358T3 (es) 2002-03-16

Family

ID=24986618

Family Applications (2)

Application Number Title Priority Date Filing Date
ES00104460T Expired - Lifetime ES2216745T3 (es) 1991-08-09 1992-07-10 Utilizacion de un inhibidor de la proteina quinasa de tau/neurofilamento pk40.
ES92915162T Expired - Lifetime ES2165358T3 (es) 1991-08-09 1992-07-10 Utilizaciones de la proteinquinasa de neurofilamento/tau pk40.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES00104460T Expired - Lifetime ES2216745T3 (es) 1991-08-09 1992-07-10 Utilizacion de un inhibidor de la proteina quinasa de tau/neurofilamento pk40.

Country Status (9)

Country Link
EP (2) EP1026237B1 (es)
JP (1) JPH06510427A (es)
AT (2) ATE262584T1 (es)
AU (1) AU675410B2 (es)
CA (1) CA2115151C (es)
DE (2) DE69233330T2 (es)
DK (2) DK1026237T3 (es)
ES (2) ES2216745T3 (es)
WO (1) WO1993003148A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200768B1 (en) * 1991-12-06 2001-03-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Method of screening for compounds that dissolve paired helical filaments
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
CA2135471A1 (en) * 1992-05-11 1993-11-25 Steven A. Stacker Receptor-type tyrosine kinase-like molecules
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
EP1299591A2 (en) * 2000-07-07 2003-04-09 Milliken & Company Textile substrates having durable water repellency and soil release and method for producing same
JP5186212B2 (ja) 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
CN104080806B (zh) * 2011-10-07 2018-01-19 Ac免疫有限公司 识别Tau的磷酸化特异抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920703068A (ko) * 1989-09-15 1992-12-17 폴 레이킨드 신경변성 질환의 치료방법
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
WO1993003177A1 (en) * 1991-08-09 1993-02-18 Massachusetts Institute Of Technology Novel tau/neurofilament protein kinases
EP0544942A1 (en) * 1991-12-06 1993-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel tools for the diagnosis and treatment of Alzheimer disease

Also Published As

Publication number Publication date
EP1026237B1 (en) 2004-03-24
DK1026237T3 (da) 2004-07-19
JPH06510427A (ja) 1994-11-24
EP1026237A3 (en) 2001-03-28
ATE206755T1 (de) 2001-10-15
DK0667898T3 (da) 2002-02-04
DE69233330T2 (de) 2005-03-10
AU675410B2 (en) 1997-02-06
ATE262584T1 (de) 2004-04-15
ES2216745T3 (es) 2004-11-01
EP0667898B1 (en) 2001-10-10
DE69232121T2 (de) 2002-06-20
DE69232121D1 (de) 2001-11-15
WO1993003148A2 (en) 1993-02-18
CA2115151C (en) 2005-05-17
CA2115151A1 (en) 1993-02-18
EP1026237A2 (en) 2000-08-09
DE69233330D1 (de) 2004-04-29
EP0667898A1 (en) 1995-08-23
WO1993003148A3 (en) 1993-04-01
AU2324092A (en) 1993-03-02

Similar Documents

Publication Publication Date Title
IE892272L (en) Novel fused heterocyclic compounds
ATE215966T1 (de) Interleukin-1-inhibitoren
DE69731285D1 (de) Langwellig fluorezierende proteine
IT8721618A0 (it) Prodecimento per la depurazione bilogica di acque reflue.
IL143670A0 (en) Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same
DK0548794T3 (da) Polyaspartamidderivater som adsorptionsmidler for galdesyrer, polyaspartamidderivater ladet med galdesyrer, fremgangsmåder
PT83535B (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de aminoacidos
DK0638068T3 (da) Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
DK0920501T3 (da) Neuritin, et neurogen
DK0789767T3 (da) Fremgangsmåde til fremstilling af oprensede papilomavirusproteiner
ES2165358T3 (es) Utilizaciones de la proteinquinasa de neurofilamento/tau pk40.
IL122606A0 (en) (S)-hydroxy-nitrile-lyase
DE69728897D1 (de) Saeugetierchemokine
DE69402201D1 (de) Phosphorhaltiges, metallurgisches silizium zur herstellung von organohalosilanen
DK0640608T3 (da) Mellemprodukter til syntese af cephalosporiner
AR022150A1 (es) Acidos nucleicos derivados de monocitos y composiciones y metodos relacionados
DE69625910T2 (de) Penamsulfone als beta-laktamase inhibitoren
DE3851979D1 (de) Substituierte Vinylcephalosporine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel.
EP0295350A3 (en) Use of n-û2-(diethylamino)ethyl¨-2-methoxy-4-û(1-h 4,5-dihydro-2-imidazolyl)amino¨-5-chlorobenzamide as an anxiolytic and antipsychotic agent
SE9604439D0 (sv) New receptor
BR9407232A (pt) Compostos de tiocarbamoíla
TR199701011A2 (xx) 1-karba-(detia)-sefalosforin t�revleri.
IT8934058V0 (it) Insieme ammortizzato per bicicletta (kit).
ITMI931034A1 (it) Processo per la preparazione di proteine inibenti i ribosomi
ATE84794T1 (de) Aminosaeure-derivate als antihypertensive.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 667898

Country of ref document: ES